Skip to main content
Acticor Biotech logo

Acticor Biotech — Investor Relations & Filings

Ticker · ALACT ISIN · FR0012519668 LEI · 969500K433EK1G89EV95 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2023-02-08 Declaration of Voting R…
Country FR France
Listing PA ALACT

About Acticor Biotech

https://www.acticor-biotech.com

Acticor Biotech is a clinical-stage biopharmaceutical company that originated as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is dedicated to developing innovative treatments for thrombotic diseases, with a primary focus on the acute phase of ischemic stroke. Its lead drug candidate, glenzocimab, is a humanized monoclonal antibody fragment designed to target platelet glycoprotein VI (GPVI), a key receptor involved in thrombosis. The therapeutic approach aims to provide an effective anti-thrombotic effect to safely manage stroke patients without increasing the risk of bleeding, a significant complication associated with existing treatments.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 janvier 2023" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of January 31, 2023). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of a specific date (31/01/2023). This type of periodic disclosure regarding the total number of shares and voting rights is a specific regulatory requirement, often related to capital structure changes or general shareholder information, but it is not a full financial report (10-K, IR) or a management/board change announcement (MANG). It most closely aligns with notifications concerning share capital or voting rights. Since the core content is the calculation and publication of the total number of shares and voting rights, it fits best under Share Issue/Capital Change (SHA) or, given its nature as a mandatory regulatory disclosure on share structure, it could also be considered a general Regulatory Filing (RNS). However, the specific focus on the total number of shares and voting rights strongly suggests a capital structure update or notification. Comparing the definitions, 'SHA' (Share Issue/Capital Change) is the most relevant category for updates on the number of shares outstanding, even if it's just a periodic count. Given the context of mandatory disclosure of share count and voting rights, SHA is the most precise fit among the specific options, although RNS is a possibility if SHA is interpreted too narrowly as only new issues/splits. Since the document explicitly details the total share count, SHA is chosen.
2023-02-08 French
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 100% confidence The provided document text is extremely short, consisting only of an image placeholder tag ("![](_page_0_Picture_0.jpeg)") and has a total length of only 27 characters. This content provides no substantive financial or regulatory information to classify it as a specific report type (like 10-K, ER, or IR). Given the minimal content and the lack of any descriptive text, it cannot be confidently classified into any specific category based on the definitions. Following the 'MENU VS MEAL' rule, it is not a report itself. The most appropriate fallback for unclassifiable or placeholder content that doesn't fit other specific categories is the general Regulatory Filings category (RNS).
2023-02-06 Russian
Inside Information / Other news releases
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of Patricia Zilliox to the Board of Directors, effective immediately, with ratification pending at the next Annual General Meeting. This content directly relates to changes in the company's board of directors and senior management structure. According to the definitions, this aligns perfectly with the 'Board/Management Information' category (Code: MANG). It is not an AGM presentation (AGM-R), a full annual report (10-K), or a general regulatory filing (RNS).
2023-02-06 English
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is a press release dated January 09, 2023, providing an update on the clinical progress of the drug glenzocimab across several ongoing studies (ACTISAVE, GREEN, LIBERATE). It details patient enrollment numbers, regulatory discussions (EMA, FDA), study designs, and next clinical steps. This content structure—a summary of operational and clinical milestones released to the public via a press release format—is characteristic of an Earnings Release (ER) or a general update. Since it is not a full financial report (10-K or IR) but rather an announcement of operational progress and key data points, it aligns best with the 'Earnings Release' category, which often includes operational updates alongside financial highlights, or potentially a Regulatory Filing (RNS) if it were purely regulatory. Given the focus on clinical milestones and the CEO quote reviewing progress since the IPO, ER is the most appropriate fit among the specific operational/financial codes, as it serves as a periodic update to investors. FY 2023
2023-01-09 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 95% confidence The document is a press release dated January 9, 2023, detailing clinical development updates for the drug glenzocimab across several ongoing and planned studies (ACTISAVE, GREEN, LIBERATE) related to cardiovascular emergencies like stroke (AVC) and myocardial infarction. It provides specific details on study designs, patient recruitment numbers, regulatory interactions (EMA, FDA), and next clinical milestones. This format—a detailed update on clinical progress, often issued outside of mandatory quarterly/annual filings—is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a detailed narrative update on strategy and clinical pipeline rather than just a brief announcement of results (ER) or a formal regulatory filing, 'Investor Presentation' (IP) is the most appropriate classification, as these often contain this level of strategic and clinical detail.
2023-01-09 French
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Capital/Financing Update Classification · 99% confidence The document is explicitly titled "HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT WITH THE BROKERAGE FIRM KEPLER CHEUVREUX" and is dated January 6, 2023, reporting data up to December 31, 2022. A half-year report covering financial/operational data for a period shorter than a full year strongly suggests an Interim/Quarterly Report (IR). Although the content specifically details a liquidity contract, the structure and timing align with periodic financial disclosures. It is not a full Annual Report (10-K), an Earnings Release (ER) which is usually just highlights, or a simple announcement of a report (RPA). Therefore, the most appropriate classification is Interim / Quarterly Report (IR).
2023-01-06 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.